Pagan, Eleonora; Ruggeri, Monica; Bianco, Nadia; Bucci, Eraldo Oreste; Graffeo, Rossella; Borner, Markus; Giordano, Monica; Gianni, Lorenzo; Rabaglio, Manuela; Freschi, Andrea; Cretella, Elisabetta; Seles, Elena; Farolfi, Alberto; Simoncini, Edda; Ciccarese, Mariangela; Rauch, Daniel; Favaretto, Adolfo; Honecker, Friedemann; Berardi, Rossana; Franzetti-Pellanda, Alessandra; ... (2024). Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer. Breast, 77(103765), p. 103765. Elsevier 10.1016/j.breast.2024.103765
|
Text
1-s2.0-S0960977624000961-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview |
PURPOSE
Although younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing to non-persistence remain poorly understood. We assessed factors associated with non-persistence to ET and described the 5-year trajectories of quality of life (QoL) and symptoms in young women (≤40 years) with hormone receptor-positive breast cancer (BC).
METHODS
We retrieved data on clinical characteristics and non-persistence from the medical annual records in the European cohort of the "Helping Ourselves, Helping Others: The Young Women's BC Study" (IBCSG 43-09 HOHO). Women completed surveys at baseline, biannually for three years, and annually for another seven years. Data collection included sociodemographic information, QoL aspects assessed by the Cancer Rehabilitation Evaluation System-Short Form and symptoms assessed by the Breast Cancer Prevention Trial symptom scales. Cox regression models were applied to identify factors associated with non-persistence.
RESULTS
The cumulative risk of interrupting ET within 5 years was 27.7 % (95 % CI, 21.5-35.2). The QoL subscale scores remained stable over 5 years, with slight improvements in the physical subscale. Hot flashes decreased (p < 0.001), while vaginal problems intensified (p < 0.001) over time. Being married without children and having difficulties interacting and communicating with the medical team were significantly associated with non-persistence.
CONCLUSIONS
Discussing the desire to conceive with partnered childless women and establishing a good relationship with the medical team may be important in addressing the non-persistence in young BC survivors. As recent data suggests the safety of pausing ET to conceive, this approach may be a reasonable future option to limit non-persistence.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Rabaglio, Manuela Elena |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0960-9776 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
17 Jul 2024 09:22 |
Last Modified: |
14 Sep 2024 00:14 |
Publisher DOI: |
10.1016/j.breast.2024.103765 |
PubMed ID: |
39002281 |
Uncontrolled Keywords: |
Adjuvant endocrine therapy Breast cancer Persistence Quality of life Young women |
BORIS DOI: |
10.48350/199002 |
URI: |
https://boris.unibe.ch/id/eprint/199002 |